Trial Profile
BEST
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2015
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms BEST
- Sponsors Biocon
- 08 Jun 2010 Results presented at ASCO 2010.
- 02 Jul 2009 Results have been reported at the 45th Annual Meeting of the American Society of Clinical Oncology
- 01 Jun 2009 Results presented at ASCO 2009, according to a YM BioSciences media release.